Diclofenac oral solution - Assertio Therapeutics/Novartis

Alternative Names: Cambia; Catafast; Dialrapid; Potassium diclofenac for oral solution; PRO-513; Voltfast

Latest Information Update: 20 Sep 2022

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Applied Pharma Research
Developer Assertio Therapeutics; CSC Pharmaceuticals Bulgaria; Novartis
Class Antimigraines; Antirheumatics; Nonsteroidal anti-inflammatories; Phenylacetates; Small molecules
Mechanism of Action Cyclooxygenase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

01 Jan 2022 Applied Pharma Research receives patent allowance for Diclofenac oral solution in USA
18 Dec 2020 Nuvo Pharmaceuticals is now called Miravo Healthcare
29 Jul 2019 Phase-I/II clinical trials in Migraine (PO) before July 2019 (Assertio Therapeutics pipeline, July 2019)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com